Here begins the text.

Revisions of PRECAUTIONS (FY2022)

Posted date Nonproprietary name
(Click on each drug name for more information
[only available in Japanese language])		 Detailed information on revisions of PRECAUTIONS
(from MHLW)		 Summary of investigation results
(from PMDA)
September 13, 2022 Riociguat PDF PDF
Atazanavir sulfate PDF
Ritonavir PDF
Lopinavir/ritonavir PDF
August 30, 2022 Hydroxychloroquine sulfate PDF PDF
Ramucirumab (genetical recombination) PDF PDF
July 20, 2022 Eszopiclone PDF PDF
Zopiclone PDF
Zolpidem tartrate PDF
Triazolam PDF
PDF
PDF
Avelumab (genetical recombination) PDF PDF
Durvalumab (genetical recombination)
Bortezomib PDF PDF
Posaconazole
Posaconazole		 PDF PDF
Iopamidol PDF PDF
Iohexol
Iomeprol PDF
July 8,
2022		 Recombinant COVID-19 (SARS-CoV-2) vaccine
(Nuvaxovid Intramuscular Injection)		 PDF Material for the Side Effect Subcommittee of the Immunization and Vaccine Section Meeting in the Health Science Council (the 81st meeting), and the 2022 Subcommittee on Drug Safety of the Committee on Drug Safety in the Pharmaceutical Affairs and Food Sanitation Council (the 6th meeting) (joint meeting) (Only in Japanese)
June 14, 2022 Cetuximab sarotalocan sodium (genetical recombination) PDF PDF
Nivolumab (genetical recombination) PDF PDF
Pembrolizumab (genetical recombination)
Vonoprazan fumarate/amoxicillin hydrate/metronidazole PDF PDF
Rabeprazole sodium/amoxicillin hydrate/metronidazole
Nirmatrelvir/ritonavir PDF PDF
Molnupiravir PDF PDF
Metronidazole (oral dosage form) PDF PDF
Metronidazole (injections) PDF
June 10, 2022 Coronavirus modified uridine RNA vaccine (SARS-CoV-2)
(Comirnaty intramuscular injection)		 PDF Material for the Side Effect Subcommittee of the Immunization and Vaccine Section Meeting in the Health Science Council (the 80th meeting), and the 2022 Subcommittee on Drug Safety of the Committee on Drug Safety in the Pharmaceutical Affairs and Food Sanitation Council (the 5th meeting) (joint meeting) (Only in Japanese)
Coronavirus modified uridine RNA vaccine (SARS-CoV-2)
(Comirnaty intramuscular injection for 5 to 11 years old)
Coronavirus modified uridine RNA vaccine (SARS-CoV-2)
(Spikevax Intrammuscular Injection (former brand name: COVID-19 Vaccine Moderna Intramuscular Injection))
May 13,
2022		 Dexamethasone (oral dosage form) (preparations indicated for pituitary suppression tests) PDF PDF
Dexamethasone (oral dosage form) (preparations not indicated for pituitary suppression tests) PDF
Dexamethasone palmitate
Dexamethasone sodium phosphate (injections) PDF
Betamethasone (oral dosage form) PDF
Betamethasone (suppositories) PDF
Betamethasone acetate/betamethasone sodium phosphate
Betamethasone sodium phosphate (enemas)
Betamethasone/d-chlorpheniramine maleate PDF
Betamethasone sodium phosphate (injections)
Teicoplanin PDF PDF
April 26,
2022		 Coronavirus modified uridine RNA vaccine (SARS-CoV-2)
(Comirnaty intramuscular injection)		 PDF -
Coronavirus modified uridine RNA vaccine (SARS-CoV-2)
(Spikevax Intrammuscular Injection (former brand name: COVID-19 Vaccine Moderna Intramuscular Injection))		 PDF -
April 4,
2022		 Interferon beta-1a (genetical recombination) PDF PDF
Appendix 5 and 6 are not included.
See the Detailed information on revisions of PRECAUTIONS.
Interferon beta-1b (genetical recombination) PDF
April 4,
2022		 Somatropin (genetical recombination) PDF PDF
Appendix 5 is not included.
See the Detailed information on revisions of PRECAUTIONS.
PDF
PDF
PDF

 

JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki,
Chiyoda-ku, Tokyo 100-0013 Japan

  • Contact us
  • Access/Map

Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.

000049091
0
Revisions of PRECAUTIONS (FY2022)
/english/safety/info-services/drugs/revision-of-precautions/0010.html
en